Your browser doesn't support javascript.
loading
An aptamer-mediated base editing platform for simultaneous knockin and multiple gene knockout for allogeneic CAR-T cells generation.
Porreca, Immacolata; Blassberg, Robert; Harbottle, Jennifer; Joubert, Bronwyn; Mielczarek, Olga; Stombaugh, Jesse; Hemphill, Kevin; Sumner, Jonathan; Pazeraitis, Deividas; Touza, Julia Liz; Francescatto, Margherita; Firth, Mike; Selmi, Tommaso; Collantes, Juan Carlos; Strezoska, Zaklina; Taylor, Benjamin; Jin, Shengkan; Wiggins, Ceri M; van Brabant Smith, Anja; Lambourne, John J.
Afiliación
  • Porreca I; Revvity, 8100 Cambridge Research Park, Cambridge CB25 9TL, UK. Electronic address: immacolata.porreca@revvity.com.
  • Blassberg R; Revvity, 8100 Cambridge Research Park, Cambridge CB25 9TL, UK.
  • Harbottle J; Revvity, 8100 Cambridge Research Park, Cambridge CB25 9TL, UK.
  • Joubert B; Revvity, 8100 Cambridge Research Park, Cambridge CB25 9TL, UK.
  • Mielczarek O; Revvity, 8100 Cambridge Research Park, Cambridge CB25 9TL, UK.
  • Stombaugh J; Revvity, 2650 Crescent Drive, Lafayette, CO 80026, USA.
  • Hemphill K; Revvity, 2650 Crescent Drive, Lafayette, CO 80026, USA.
  • Sumner J; AstraZeneca, Discovery Sciences, R&D, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.
  • Pazeraitis D; AstraZeneca, Discovery Sciences, R&D, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.
  • Touza JL; AstraZeneca, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Pepparedsleden 1, 431 83 Mölndal, Sweden.
  • Francescatto M; AstraZeneca, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Pepparedsleden 1, 431 83 Mölndal, Sweden.
  • Firth M; AstraZeneca, Discovery Sciences, R&D, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.
  • Selmi T; Revvity, 8100 Cambridge Research Park, Cambridge CB25 9TL, UK.
  • Collantes JC; Departamento de Biotecnología, Colegio de Ciencias Biológicas y Ambientales, Universidad San Francisco de Quito, Campus Cumbayá, Casilla Postal 17-1200-841, Quito 170901, Ecuador.
  • Strezoska Z; Revvity, 2650 Crescent Drive, Lafayette, CO 80026, USA.
  • Taylor B; AstraZeneca, Discovery Sciences, R&D, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.
  • Jin S; Pharmacology Department, Rutgers, The State University of New Jersey, Robert Wood Johnson Medical School, 675 Hoes Lane West, Piscataway, NJ 08854, USA.
  • Wiggins CM; Revvity, 8100 Cambridge Research Park, Cambridge CB25 9TL, UK.
  • van Brabant Smith A; Revvity, 2650 Crescent Drive, Lafayette, CO 80026, USA.
  • Lambourne JJ; Revvity, 8100 Cambridge Research Park, Cambridge CB25 9TL, UK.
Mol Ther ; 2024 Jun 26.
Article en En | MEDLINE | ID: mdl-38937969
ABSTRACT
Gene editing technologies hold promise for enabling the next generation of adoptive cellular therapies. In conventional gene editing platforms that rely on nuclease activity, such as clustered regularly interspaced short palindromic repeats CRISPR-associated protein 9 (CRISPR-Cas9), allow efficient introduction of genetic modifications; however, these modifications occur via the generation of DNA double-strand breaks (DSBs) and can lead to unwanted genomic alterations and genotoxicity. Here, we apply a novel modular RNA aptamer-mediated Pin-point base editing platform to simultaneously introduce multiple gene knockouts and site-specific integration of a transgene in human primary T cells. We demonstrate high editing efficiency and purity at all target sites and significantly reduced frequency of chromosomal translocations compared with the conventional CRISPR-Cas9 system. Site-specific knockin of a chimeric antigen receptor and multiplex gene knockout are achieved within a single intervention and without the requirement for additional sequence-targeting components. The ability to perform complex genome editing efficiently and precisely highlights the potential of the Pin-point platform for application in a range of advanced cell therapies.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Mol Ther Asunto de la revista: BIOLOGIA MOLECULAR / TERAPEUTICA Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Mol Ther Asunto de la revista: BIOLOGIA MOLECULAR / TERAPEUTICA Año: 2024 Tipo del documento: Article